Clal Biotechnology reported ILS5.15M in Operating Expenses for its fiscal quarter ending in December of 2022.





Operating Expenses Change Date
Arca Biopharma USD 34.43M 326K Dec/2025
aTyr Pharma USD 85.61M 58.67M Dec/2025
Bio Path USD 488K 4.07M Sep/2025
Brainstorm Cell Therapeutics USD 2.24M 197K Dec/2025
Cara Therapeutics USD 5.94M 983K Sep/2025
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.29M 1.51M Dec/2025
Immunic USD 25.73M 2.91M Sep/2024
Infinity Pharmaceuticals USD 10.7M 1.54M Jun/2023
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
RedHill Biopharma USD 5.51M 1.08M Jun/2024
TherapeuticsMD USD 1.41M 50K Jun/2024